BMS 181174 is an analog of Mitomycin C (M371900) with activity against a range of tumour cell lines and xenografts, including MMC-resistant tumours. However, phase I clinical trials from Bristol-Myers Squibb demonstrated that the toxicity profile of BMS 181174 was no more favourable than that of mitomycin.